ofatumumab MS
Selected indexed studies
- Efficacy of Ofatumumab and Teriflunomide in Patients With Relapsing MS From Racial/Ethnic Minority Groups: ASCLEPIOS I/II Subgroup Analyses. (Neurology, 2024) [PMID:39018512]
- Efficacy and safety of four-year ofatumumab treatment in relapsing multiple sclerosis: The ALITHIOS open-label extension. (Mult Scler, 2023) [PMID:37691530]
- High-Efficacy Therapies for Treatment-Naïve Individuals with Relapsing-Remitting Multiple Sclerosis. (CNS Drugs, 2022) [PMID:36350491]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Efficacy and safety of four-year ofatumumab treatment in relapsing multiple sclerosis: The ALITHIOS open-label extension. (2023) pubmed
- High-Efficacy Therapies for Treatment-Naïve Individuals with Relapsing-Remitting Multiple Sclerosis. (2022) pubmed
- B cells in multiple sclerosis - from targeted depletion to immune reconstitution therapies. (2021) pubmed
- Anti-CD20 therapies in multiple sclerosis: From pathology to the clinic. (2023) pubmed
- Efficacy of Ofatumumab and Teriflunomide in Patients With Relapsing MS From Racial/Ethnic Minority Groups: ASCLEPIOS I/II Subgroup Analyses. (2024) pubmed
- Five-Year Safety and Efficacy Outcomes with Ofatumumab in Patients with Relapsing Multiple Sclerosis. (2025) pubmed
- Anti-CD20 therapies for multiple sclerosis: current status and future perspectives. (2022) pubmed
- Drugs Targeting CD20 in Multiple Sclerosis: Pharmacology, Efficacy, Safety, and Tolerability. (2024) pubmed
- Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: Results from ASCLEPIOS I and II. (2022) pubmed
- Key characteristics of anti-CD20 monoclonal antibodies and clinical implications for multiple sclerosis treatment. (2024) pubmed